EMEA-001995-PIP01-16-M03
Key facts
Invented name |
Breyanzi
|
Active substance |
Lisocabtagene maraleucel
|
Therapeutic area |
Oncology
|
Decision number |
P/0558/2021
|
PIP number |
EMEA-001995-PIP01-16-M03
|
Pharmaceutical form(s) |
Dispersion for infusion
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|